WO1991000856A3 - DERIVES DE (1,2N) et (3,2N)-CARBOCYCLIQUE-2-AMINO TETRALINES - Google Patents

DERIVES DE (1,2N) et (3,2N)-CARBOCYCLIQUE-2-AMINO TETRALINES

Info

Publication number
WO1991000856A3
WO1991000856A3 PCT/US1990/003551 US9003551W WO9100856A3 WO 1991000856 A3 WO1991000856 A3 WO 1991000856A3 US 9003551 W US9003551 W US 9003551W WO 9100856 A3 WO9100856 A3 WO 9100856A3
Authority
WO
WIPO (PCT)
Prior art keywords
carbocyclic
tetralin derivatives
amino tetralin
amino
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1990/003551
Other languages
English (en)
Other versions
WO1991000856A2 (fr
Inventor
Chiu-Hong Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Priority to KR1019920700056A priority Critical patent/KR0151699B1/ko
Priority to DE69030665T priority patent/DE69030665T2/de
Priority to AU61453/90A priority patent/AU648032B2/en
Priority to EP90911443A priority patent/EP0482084B1/fr
Publication of WO1991000856A2 publication Critical patent/WO1991000856A2/fr
Publication of WO1991000856A3 publication Critical patent/WO1991000856A3/fr
Priority to US07/803,287 priority patent/US5491236A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/08—Aza-anthracenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne des tétralines d'utilité thérapeutique ainsi que leurs sels d'addition acide pharmaceutiquement acceptables de formule (I) dans laquelle R, R1 et A sont définis dans la revendication 1. Ces composés sont utiles pour traiter les troubles du système nerveux central.
PCT/US1990/003551 1989-07-13 1990-06-27 DERIVES DE (1,2N) et (3,2N)-CARBOCYCLIQUE-2-AMINO TETRALINES Ceased WO1991000856A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR1019920700056A KR0151699B1 (ko) 1989-07-13 1990-06-27 (1,2n) 및 (3,2n)-카보사이클릭-2-아미노테트랄린 유도체
DE69030665T DE69030665T2 (de) 1989-07-13 1990-06-27 (1,2n) und (3,2n)-karbozyklische-2-amino-tetralinderivate
AU61453/90A AU648032B2 (en) 1989-07-13 1990-06-27 (1,2N) and (3,2N)-carbocyclic-2-amino tetralin derivatives
EP90911443A EP0482084B1 (fr) 1989-07-13 1990-06-27 DERIVES DE (1,2N) et (3,2N)-CARBOCYCLIQUE-2-AMINO TETRALINES
US07/803,287 US5491236A (en) 1989-07-13 1991-12-04 (1,2N) and (3,2N)-carbocyclic-2-amino tetralin derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37952689A 1989-07-13 1989-07-13
US379,526 1989-07-13

Publications (2)

Publication Number Publication Date
WO1991000856A2 WO1991000856A2 (fr) 1991-01-24
WO1991000856A3 true WO1991000856A3 (fr) 1991-03-21

Family

ID=23497619

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/003551 Ceased WO1991000856A2 (fr) 1989-07-13 1990-06-27 DERIVES DE (1,2N) et (3,2N)-CARBOCYCLIQUE-2-AMINO TETRALINES

Country Status (11)

Country Link
US (1) US5491236A (fr)
EP (1) EP0482084B1 (fr)
JP (1) JP3005287B2 (fr)
KR (1) KR0151699B1 (fr)
AT (1) ATE152708T1 (fr)
AU (1) AU648032B2 (fr)
CA (1) CA2057912C (fr)
DE (1) DE69030665T2 (fr)
DK (1) DK0482084T3 (fr)
ES (1) ES2100886T3 (fr)
WO (1) WO1991000856A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486611A (en) * 1989-07-13 1996-01-23 The Upjohn Company Carboxamido-(1,2N)-carbocyclic-2-aminotetralin derivatives
EP0510068B1 (fr) * 1990-01-11 1999-04-14 PHARMACIA & UPJOHN COMPANY NOUVEAUX COMPOSES HETEROCYCLIQUES DE 6,7,8,9-TETRAHYDRO-3H-BENZ(e)INDOLE AGISSANT SUR LE SYSTEME NERVEUX CENTRAL
AU2153592A (en) * 1991-05-20 1993-01-08 Upjohn Company, The Carboxamido-(3,2n)-carbocyclic-2-aminotetralin derivatives
JP3155276B2 (ja) * 1991-05-20 2001-04-09 ファルマシア・アンド・アップジョン・カンパニー カルボキサミド−（１，２ｎ）−カルボサイクリック−２−アミノテトラリン誘導体
TW239127B (fr) * 1991-12-20 1995-01-21 Hoffmann La Roche
NZ260667A (en) * 1993-06-10 1997-05-26 Lilly Co Eli Preventing emesis or treating sexual dysfunction using tetrahydrobenz[cd]indole 6-carboxamides
GB9612153D0 (en) * 1996-06-11 1996-08-14 Smithkline Beecham Plc Compounds
DE19834714A1 (de) * 1998-07-31 2000-02-03 Boehringer Ingelheim Pharma Neue 2,3,3a,4,9,9a-Hexahydro-8-hydroxy-1H-ben[f]indole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0004003D0 (en) * 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
GB0517292D0 (en) 2005-08-24 2005-10-05 Univ Dundee Cell migration modulating compounds

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2044172A1 (de) * 1969-09-08 1971-03-25 Laboratoires Jacques Logeais, S A , Issv les Mouhneaux, Seine (Frankreich) Neue Pyrroldenvate, ein Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimittelzubereitungen
FR2146503A1 (en) * 1971-07-22 1973-03-02 Tanabe Seiyaku Co Hexahydro-benz(e) indole derivs. - useful as non-addictive analgetics
US3839338A (en) * 1968-05-09 1974-10-01 W Michne 1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO{8 g{9 QUINOLINES
EP0059553A2 (fr) * 1981-03-02 1982-09-08 Smithkline Beckman Corporation Composés d'octahydrobenzo(f)quinoline
GB2134515A (en) * 1983-02-01 1984-08-15 Sandoz Ltd Benzoquinolines
EP0127597A1 (fr) * 1983-04-27 1984-12-05 Per Arvid Emil Carlsson Dérivés de l'octahydrobenzo (f) quinoléine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1555553A (fr) * 1967-07-05 1969-01-31
US3898235A (en) 1970-12-02 1975-08-05 Sterling Drug Inc Octahydrobenzo {8 g{9 {0 quinolines and hexahydroindeno {8 1,2,b{9 {0 pyridines
US4234731A (en) * 1979-01-05 1980-11-18 Bristol-Myers Company 9-Oxobenzomorphan process
US4618683A (en) * 1982-06-01 1986-10-21 Abbott Laboratories Tetrahydro-6,7-dimethoxy-1H-benz[e]isoinodolines useful in the treatment of hypertension and as sedatives
DE3719924A1 (de) * 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline
CA2011640A1 (fr) * 1989-03-20 1990-09-20 F. Hoffmann-La Roche Ag Derives de quinoline
US5244888A (en) * 1989-11-17 1993-09-14 Abbott Laboratories 5-HT selective agents
US5248677A (en) * 1990-03-30 1993-09-28 Abbott Laboratories Biogentic amine uptake inhibitors
US5180733A (en) * 1990-03-30 1993-01-19 Abbott Laboratories Biogenic amine uptake inhibitors
TW239127B (fr) * 1991-12-20 1995-01-21 Hoffmann La Roche

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839338A (en) * 1968-05-09 1974-10-01 W Michne 1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO{8 g{9 QUINOLINES
DE2044172A1 (de) * 1969-09-08 1971-03-25 Laboratoires Jacques Logeais, S A , Issv les Mouhneaux, Seine (Frankreich) Neue Pyrroldenvate, ein Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimittelzubereitungen
FR2146503A1 (en) * 1971-07-22 1973-03-02 Tanabe Seiyaku Co Hexahydro-benz(e) indole derivs. - useful as non-addictive analgetics
EP0059553A2 (fr) * 1981-03-02 1982-09-08 Smithkline Beckman Corporation Composés d'octahydrobenzo(f)quinoline
GB2134515A (en) * 1983-02-01 1984-08-15 Sandoz Ltd Benzoquinolines
EP0127597A1 (fr) * 1983-04-27 1984-12-05 Per Arvid Emil Carlsson Dérivés de l'octahydrobenzo (f) quinoléine

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Volume 86, 1977, (Columbus Ohio, US), A. KUMAR et al.: "Studies on Analgesic-Narcotic Antagonists: Synthesis of N-Substituted 1,2,3,4,4a,5,6,10b-Octahydrobenzo(f)-Quinolines", see page 456, Abstract 5285g, & Indian J. Chem., Sect. B 1976, 14B(7), 556-7 *
Journal of Medicinal Chemistry, Volume 22, No. 4, 1979, American Chemical Society, (US), J.G. CANNON et al.: "Rigid Congeners of Dopamine Based on Octahydrobenzo(f) Quinoline: Peripheral and Central Effects", pages 341-347 see compounds 1-7,13-16 *
Journal of Medicinal Chemistry, Volume 23, No. 1, January 1980, American Chemical Society, (US), J.G. CANNON et al.: "Congeners of the beta Conformer of Dopamine Derived from Cis- and Trans-Octahydrobenzo(f) Quinoline and Trans-Octahydrobenzo(g) Quinoline", pages 1-5 see table I *
Journal of Medicinal Chemistry, Volume 25, No. 8, 1982, American Chemical Society, (US), H. WIKSTROM et al.: "Monophenolic Octahydrobenzo (f) Quinolines: Central Dopamine- and Serotoninreceptor Stimulating Activity", pages 925-931 see compounds 6-19 *
Journal of Medicinal Chemistry, Volume 27, No. 2, 1984, American Chemical Society, (US),J.G. CANNON et el.: "Conformationally Restricted Congeners of Dopamine Derived from Octahydrobenzo (g) Quinoline and Octahydrobenzo (f) Quinoline", pages 190-195 see compounds 16,42-50 *
Journal of Medicinal Chemistry, Volume 29, No. 10, 1986, American Chemical Society, (US), J.G. CANNON et al.: " Assessment of a Potential Dopaminergic Prodrug Moiety in Several Ring Systems", pages 2016-2020 see cmpunds 4a-4d *
Journal of Medicinal Chemistry, Volume 29, No. 12, 1986, American Chemical Society, (US), J.G. CANNON et al.: "p-Dimethoxysubstituted Trans-Octahydrobenzo (f) - and - (g) Quinolines : Synthesis and Assessment of Dopaminergic Agonist Effects", pages 2529-2534 see compounds 8,9,13 *
Journal of Medicinal Chemistry, Volume 30, No. 12, 1987, American Chemical Society, (US), H. WIKSTROM et al.: "N-Substituted 1,2,3,4,4a,5,6,10b-Octahydrobenzo(f) Quinolines and 3-Phenylpiperidines: Effects on Central Dopamine and delta Receptors", pages 2169-2174 see compounds 11-33 *
Journal of Medicinal Chemistry, Volume 30, No. 9, September 1987, American Chemical Society, (US), H. WIKSTROM et al.: "Resolved Cis-10-Hydroxy-4-n-Propyl-1,2,3,4,4a,5,6,10b-Octahydrobenzo f Quinoline: Central Serotonin Stimulatng Properties", pages 1567-1573 see page 1567 *

Also Published As

Publication number Publication date
JPH04507408A (ja) 1992-12-24
AU648032B2 (en) 1994-04-14
CA2057912C (fr) 1996-10-29
KR0151699B1 (ko) 1998-10-15
ES2100886T3 (es) 1997-07-01
DE69030665T2 (de) 1997-10-02
EP0482084A1 (fr) 1992-04-29
ATE152708T1 (de) 1997-05-15
DK0482084T3 (da) 1997-11-03
US5491236A (en) 1996-02-13
CA2057912A1 (fr) 1991-01-14
WO1991000856A2 (fr) 1991-01-24
DE69030665D1 (de) 1997-06-12
EP0482084B1 (fr) 1997-05-07
JP3005287B2 (ja) 2000-01-31
KR927003529A (ko) 1992-12-18
AU6145390A (en) 1991-02-06

Similar Documents

Publication Publication Date Title
CA2051399A1 (fr) Derives de la 2-aminotetraline utile therapeutiquement
CA2141048A1 (fr) Derives de substitution benzylamino d'heterocycles non aromatiques azotes
FI113651B (fi) Menetelmä terapeuttisesti käyttökelpoisten bentsimidatsoliyhdisteiden valmistamiseksi
CA2134964A1 (fr) Derives aza-bicycliques pontes, utilises comme antagonistes de la substance p
IE880297L (en) Indanes and related heterocycles
HU9301155D0 (en) Methods for producing steroide derivatives and for their application in medical treatment
IE883003L (en) Pyridine derivatives and related intermediates
WO1991000856A3 (fr) DERIVES DE (1,2N) et (3,2N)-CARBOCYCLIQUE-2-AMINO TETRALINES
RU94039284A (ru) Производные пиперазина, способ их получения, фармкомпозиция и ее использование
WO1999004770A3 (fr) Composition pharmaceutique active dans la reduction de production de proteine mcp-1
CA2007261A1 (fr) Nouveaux derives de tetraline
SE9702716D0 (sv) Substituted phenylazacycloalkanes in the treatment of cognitive disorders
GR3005176T3 (fr)
GR871549B (en) Amino acid derivative anticonvulsant
CA2128202A1 (fr) Derives alkyles de la trazodone agissant sur le snc
CA2130678A1 (fr) 2,3,4,5-tetrahydro-1h-3-benzazepines et leurs sels d'addition d'acide acceptables comme produits pharmaceutiques
DK1025101T3 (da) Naphtho-imidazo[1,2-a]pyridinderivater, deres fremstilling og deres anvendelse ved behandlingen af sygdomme i centralnervesystemet
AU7761587A (en) Process
MXPA98005355A (es) Derivados de 5-[(heteroaril) alquil]-3 -oxo-pirido [1, 2-a]bencimidazol -4-carboxamida utiles en el tratamiento de trastornos del sistema nervioso central.
WO1992021654A3 (fr) Derives de carboxamido-(3,2n)-2-aminotetralinecarbocyclique
EP0301834A3 (fr) Dérivés de l'acide benzoyloxyacétique, préparation et formules les contenant pour usage thérapeutique
AU6214286A (en) Novel n-substituted 3,4 - dihydropyrimidine derivatives as agents for treating disorders of cardiovascular system
SE8305362D0 (sv) Novel substituted phenylazacycloalkanes, processes for preparation and pharmaceutical preparations for such compounds
CA2171972A1 (fr) Derives de substitution heteroarylamino et heteroarylsulfonamido de 3-benzylaminomethylpiperidines et composes apparentes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB IT LU ML MR NL SE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1-35,DESCRIPTION,REPLACED BY NEW PAGES 1-43 AND PAGES 36-39,CLAIMS,REPLACED BY NEW PAGES 44-48;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 1990911443

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2057912

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1990911443

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1990911443

Country of ref document: EP

ENP Entry into the national phase

Ref country code: CA

Ref document number: 2057912

Kind code of ref document: A

Format of ref document f/p: F